Form 8-K

8-K — HeartSciences Inc.

Accession: 0001213900-26-106500

Filed: 2026-10-02

Period: 2026-09-29

CIK: 0001468492

SIC: 6199 (FINANCE SERVICES)

Item: Entry into a Material Definitive Agreement

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Financial Statements and Exhibits

Documents

8-K — ea0307437-8k_heart.htm (Primary)

EX-10.1 — AMENDMENT NO. 8 TO LOAN AND SECURITY AGREEMENT BY AND BETWEEN HEARTSCIENCES INC. AND FRONT RANGE VENTURES LLC, DATED SEPTEMBER 29, 2026 (ea030743701ex10-1.htm)

EX-10.2 — NO. 4 AMENDED AND RESTATED SECURED PROMISSORY NOTE BY AND BETWEEN HEARTSCIENCES INC. AND FRONT RANGE VENTURES LLC, DATED SEPTEMBER 29, 2026 (ea030743701ex10-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0307437-8k_heart.htm · Sequence: 1

false

0001468492

2026-09-29

0001468492

us-gaap:CommonStockMember

2026-09-29

0001468492

HSCS:WarrantsMember

2026-09-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report

(Date of earliest event reported): September 29, 2026

HEARTSCIENCES

INC.

(Exact name of Registrant as Specified in Its

Charter)

Texas

001-41422

26-1344466

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

550 Reserve Street, Suite 360

Southlake, Texas

76092

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s

Telephone Number, Including Area Code: (682) 237-7781

n/a

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title

of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

HSCS

The Nasdaq Stock Market LLC

Warrants

HSCSW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

previously reported, HeartSciences Inc. (the “Company”) entered into a Loan and Security Agreement on April 24, 2020 (the

“Original Loan Agreement”), as amended by Amendment No. 1 to the Loan and Security Agreement, dated September 30, 2021 (the

“No. 1 Amendment”), Amendment No. 2 to the Loan and Security Agreement, dated November 3, 2021 (the “No. 2 Amendment”),

Amendment No. 3 to the Loan and Security Agreement, dated May 24, 2022 (the “No. 3 Amendment”), Amendment No. 4 to the Loan

and Security Agreement, dated January 19, 2023 (the “No. 4 Amendment”), Amendment No. 5 to the Loan and Security Agreement,

dated September 29, 2023 (the “No. 5 Amendment”), Amendment No. 6 to the Loan and Security Agreement, dated August 19, 2024

(the “No. 6 Amendment”), and Amendment No. 7 to the Loan and Security Agreement, dated September 26, 2025 (the “No.

7 Amendment” and, collectively with the Original Loan Agreement, the No. 1 Amendment, the No. 2 Amendment, the No. 3 Amendment,

the No. 4 Amendment, the No. 5 Amendment and the No. 6 Amendment, the “Loan Agreement”), for the Company to borrow $500,000

from Front Range Ventures LLC (“FRV”) as evidenced by a secured, non-convertible promissory note, dated April 24, 2020, as

amended by the Amended and Restated Secured Promissory Note, dated September 29, 2023, the Amended and Restated Secured Promissory Note

dated August 19, 2024 and the Amended and Restated Secured Promissory Note dated September 26, 2025 (as amended, the “Note”).

The Note accrued interest at a rate of 12% per annum, compounded annually, and had an original maturity date of September 30, 2021, which

was subsequently amended to, among other things, extend the maturity date on several occasions.

September 29, 2026, the Company and FRV entered into Amendment No. 8 to the Loan Agreement (the “Amended Loan Agreement”)

and No. 4 Amended and Restated Secured Promissory Note (the “Amended Note”), pursuant to which the parties agreed (i) to further

extend the maturity date of the Note to the earlier to occur of (x) the date that is 2 business days following the closing of the proposed

business combination between the Company and Fortitude Mining Holdings, Inc. announced on June 23, 2026 and (y) January 29, 2027 (the

“Maturity Date”), and (ii) for the Company to pay the outstanding accrued interest under the Note as follows: (x) a payment

of accrued unpaid interest as of September 30, 2026 on or before such date, and (y) all accrued unpaid interest due thereafter shall be

payable on the Maturity Date. The Company may elect to repay all or any part of the outstanding principal amount of the Amended Note in

its sole discretion at any time prior to the Maturity Date, provided such repayment shall not be less than $50,000 and shall first be

applied to accrued interest and thereafter to the outstanding principal amount.

Item 2.03 Creation

of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

To the extent required

by Item 2.03 of Form 8-K, the information set forth in Item 1.01 above is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Description

10.1*

Amendment No. 8 to Loan and Security Agreement by and between HeartSciences Inc. and Front Range Ventures LLC, dated September 29, 2026.

10.2*

No. 4 Amended and Restated Secured Promissory Note by and between HeartSciences Inc. and Front Range Ventures LLC, dated September 29, 2026.

104**

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEARTSCIENCES INC.

Date: October 2, 2026

By:

/s/ Andrew Simpson

Name:

Andrew Simpson

Title:

President, Chief Executive Officer and Chairman of the Board of Directors

EX-10.1 — AMENDMENT NO. 8 TO LOAN AND SECURITY AGREEMENT BY AND BETWEEN HEARTSCIENCES INC. AND FRONT RANGE VENTURES LLC, DATED SEPTEMBER 29, 2026

EX-10.1

Filename: ea030743701ex10-1.htm · Sequence: 2

Exhibit 10.1

AMENDMENT NO. 8

LOAN AND SECURITY AGREEMENT

THIS AMENDMENT NO. 8 TO LOAN

AND SECURITY AGREEMENT (this “No. 8 Amendment”) is made and entered into as of September 29, 2026, by and among HeartSciences

Inc., a Texas corporation (the “Company”), Front Range Ventures LLC, a Wyoming limited liability company, or its assigns

(“FRV” or the “Lender”) as defined in the Original Agreement (as defined below).

WITNESSETH:

WHEREAS, the Company and the

Lender (collectively, the “Parties”) have previously entered into that certain Loan and Security Agreement dated on

or around April 24, 2020 (the “Original Agreement”), Amendment No. 1 to the Loan and Security Agreement dated September

30, 2021 (the “No. 1 Amendment”), Amendment No. 2 to the Loan and Security Agreement dated November 3, 2021 (the No.

2 Amendment”), and Amendment No. 3 to the Loan and Security Agreement dated May 24, 2022 (the “No. 3 Amendment”),

Amendment No. 4 to the Loan and Security Agreement dated January 19, 2023, (the “No. 4 Amendment”), Amendment No. 5

to the Loan and Security Agreement dated September 29, 2023, (the “No. 5 Amendment”), Amendment No. 6 to the Loan and

Security Agreement dated August 19, 2024 (the “No. 6 Amendment”), Amendment No. 7 to the Loan and Security Agreement

dated September 26, 2025 (the “No. 7 Amendment” and, collectively with the Original Agreement, the No. 1 Amendment,

the No. 2 Amendment, the No. 3 Amendment, the No. 4 Amendment, the No. 5 Amendment, the No. 6 Amendment, and the No. 7 Amendment, the

“Loan Agreement”); and

WHEREAS, the Company and FRV

desire to further amend the maturity date and interest repayment dates with respect to the Loan Agreement and related FRV Note.

NOW, THEREFORE, in consideration

of the representations, warranties, covenants, agreements and conditions set forth herein, the Loan Agreement, and the other Transaction

Agreements, the Company and the Lender, intending to be legally bound, hereby agree as follows:

Section 1. Capitalized

Terms. Except as otherwise provided herein, capitalized terms used in this No. 8 Amendment shall have the meaning set forth in the

Loan Agreement.

Section 2. Amendments.

The Loan Agreement is hereby amended as follow:

(i) The first paragraph of

Section 2.1 of the Loan Agreement is hereby amended, such that Section 2.1 of the Loan Agreement is hereby amended to read in its entirety,

as follows:

2.1 Interest.

(a) Interest will accrue on the outstanding

Principal Amount at the rate of twelve percent (12%) per annum, compounded annually (“Accrued Interest”). The Company shall

pay all Accrued Interest as follows: (i) a payment of Accrued Interest on September 30, 2026 and (ii) thereafter all Accrued Interest

due shall be payable on the “FRV Maturity Date” (as defined in Section 3.1).

(ii) The first paragraph of

Section 3.1 of the Loan Agreement is hereby amended, such that Section 3.1 of the Loan Agreement is hereby amended to read in its entirety,

as follows:

“3.1 Maturity Date. The

outstanding Principal Amount shall be due and payable on the earlier to occur of (i) the date that is two (2) business days following

the closing of the proposed business combination with Fortitude Mining Holdings, Inc. announced on June 23, 2026 and (ii) January 29,

2027 (the “FRV Maturity Date”) and Accrued Interest shall be paid in accordance with Section 2.1 (a) above.”

(iii) A new second paragraph

Section 3.2 of the Loan Agreement is hereby added to read in its entirety, as follows:

“3.2 Early Repayment. The

Company may elect to repay all or any part of the Loan Agreement at its sole discretion at any time prior to the Maturity Date. Any such

repayment shall be in an amount no less than $50,000 and shall first be applied to Accrued Interest and thereafter to the outstanding

Principal Amount.”

Section 3. Release of

Claims Against Lender.

THE COMPANY, BY SIGNING THIS

NO. 8 AMENDMENT, HEREBY ABSOLUTELY AND UNCONDITIONALLY RELEASES AND FOREVER DISCHARGES LENDER AND ANY AND ALL OF THEIR PARENT COMPANIES,

SUBSIDIARY COMPANIES, AFFILIATED COMPANIES, INSURERS, INDEMNITORS, SUCCESSORS AND ASSIGNS TOGETHER WITH ALL OF THEIR RESPECTIVE PRESENT

AND FORMER MANAGERS, DIRECTORS, OFFICERS, AGENTS AND EMPLOYEES FROM ANY AND ALL CLAIMS, DEMANDS OR CAUSES OF ACTION OF ANY KIND, NATURE

OR DESCRIPTION, WHETHER ARISING IN LAW OR EQUITY OR UPON CONTRACT OR TORT OR UNDER ANY STATE OR FEDERAL LAW OR OTHERWISE, WHICH THE COMPANY

HAS HAD, NOW HAS, OR HAS MADE CLAIM TO HAVE AGAINST ANY SUCH PARTY FOR OR BY REASON OF ANY ACT, OMISSION, MATTER, CAUSE OR THING WHATSOEVER

ARISING FROM THE BEGINNING OF TIME TO AND INCLUDING THE DATE OF THIS AMENDMENT, WHETHER SUCH CLAIMS, DEMANDS AND CAUSES OF ACTION ARE

MATURED OR UNMATURED OR KNOWN OR UNKNOWN.

Section 4. Ratification;

Amended and Restated Notes. The Loan Agreement, as amended by this No. 8 Amendment, is, and shall continue to be, in full force and

effect and is hereby ratified and confirmed in all respects, and, effective as of the date of this Amendment No. 8.

Section 5. Execution

in Several Counterparts. This No. 8 Amendment may be executed in several counterparts or by separate instruments and by facsimile

transmission and all of such counterparts and instruments shall constitute one agreement, binding on all of the Parties hereto.

Section 6. Headings.

The headings in this No. 8 Amendment are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

Section 7. Governing

Law. The laws of the State of Texas shall govern this No. 8 Amendment without regard to principles of conflict of laws.

Section 8. Original

Agreements. Except as expressly amended by this No. 8 Amendment, the Transaction Agreements shall remain in full force and effect

and all of the terms of the Transaction Agreements are hereby incorporated into this No. 8 Amendment.

[Remainder of this page deliberately left blank]

IN WITNESS WHEREOF, the

undersigned have executed this No. 8 Amendment as of the day and year first above written.

COMPANY:

HEARTSCIENCES INC

By:

/s/ Andrew Simpson

Printed:

Andrew Simpson

Title:

CEO

LENDER:

FRONT RANGE VENTURES, LLC.

By:

/s/ Alix Storrer

Printed:

Alix Storrer

Title:

AVP, Trust Officer

EX-10.2 — NO. 4 AMENDED AND RESTATED SECURED PROMISSORY NOTE BY AND BETWEEN HEARTSCIENCES INC. AND FRONT RANGE VENTURES LLC, DATED SEPTEMBER 29, 2026

EX-10.2

Filename: ea030743701ex10-2.htm · Sequence: 3

Exhibit 10.2

No. 4 Amended and

Restated SECURED PROMISSORY NOTE

Southlake, Texas

Original Issue Date: April 24, 2020

THIS No. 4 AMENDED AND RESTATED

SECURED PROMISSORY NOTE (this “Note”), dated as of September 29 __, 2026, amends and restates the Secured Promissory

Note dated April 24, 2020, the Amended and Restated Secured Promissory Note dated September 29, 2023, the Amended and Restated Secured

Promissory Note dated August 19, 2024, and the Amended and Restated Secured Promissory Note dated September 26, 2025, in the original

principal amount of $500,000, (the “Original Note”) executed by HeartSciences Inc., a Texas corporation

(“Payor”), in favor of Front Range Ventures LLC, a Wyoming limited liability company, or its assigns

(“Holder,” and together with Payor, the “Parties”). Payor and Holder desire to amend

and restate the Original Note in its entirety as follows:

For value received, Payor

promises to pay to Holder the outstanding principal amount balance as set forth in the last entry on the schedule of loans annexed to

the Original Note (the “Schedule of Loans”) and interest on the outstanding principal amount balance at the

rate of twelve percent (12%) per annum, compounded annually. Such interest shall commence on the date of each loan and continue to accrue

until paid in full. Interest shall be computed based on a year of three hundred sixty-five (365) days for the actual number of days elapsed.

All principal and interest will be paid in accordance with the Loan Agreement (as defined below). Capitalized terms not otherwise defined

herein shall have the meaning ascribed in that certain Loan and Security Agreement dated as of April 24, 2020, as amended by Amendment

No. 1 to the Loan and Security Agreement dated September 30, 2021, Amendment No. 2 to the Loan and Security Agreement dated November 3,

2021, Amendment No. 3 to the Loan and Security Agreement dated May 24, 2022, Amendment No. 4 to the Loan and Security Agreement dated

January 19, 2023, Amendment No. 5 to the Loan and Security Agreement dated September 29, 2023, Amendment No. 6 to the Loan and Security

Agreement dated August 19, 2024, Amendment No. 7 to the Loan and Security Agreement dated September 26, 2025, and Amendment No. 8 to the

Loan and Security Agreement dated September __, 2026 (as amended, the “Loan Agreement”).

1. All

payments of interest and principal shall be in lawful money of the United States of America in cash, by certified check, or wire transfer.

All payments shall be applied first to accrued expenses due under this Note, next to interest and thereafter to principal.

2. Payor

shall pay on demand all costs and expenses incurred by Holder in connection with Holder’s enforcement of Payor’s obligations

under this Note and the security agreement set forth in the Loan Agreement (the “Security Agreement”), including,

without limitation, Holder’s reasonable attorney’s fees and costs.

3. The

outstanding balance of any amount owing under this Note that is not paid when due under the terms of this Note shall bear interest at

rate of 18% per annum, compounded annually.

4. All

payments of principal and interest shall be made in cash, certified check or by wire transfer to Holder at PO Box 938, Jackson, WY 83001

or at such other place as Holder may designate in writing.

Page 1 of 5

5. Payor

shall make all payments under this Note without defense, set-off or counterclaim on its part.

6. The

occurrence of any one or more of the following shall constitute an “Event of Default” hereunder:

(a) Payor

fails to pay timely any amount due under this Note on the date the same becomes due and payable.

(b) Payor

breaches any provision of this Note or the Loan Agreement (together, the “Transaction Agreements”), or materially

breach any representation or warranty of Payor made herein, in the other Transaction Agreements, or in any other agreement, statement,

certificate, or communication given to Holder pursuant to the Note or the other Transaction Agreements shall be false or misleading in

any material respect when made.

shall (i) fail to make any payment when due under the terms of any bond, debenture, note or other evidence of indebtedness for money borrowed

to be paid by Payor and such failure shall continue beyond any period of grace provided with respect thereto, or (ii) default in the observance

or performance of any other agreement, term or condition contained in any bond, debenture, note or other evidence of indebtedness for

borrowed money, and the effect of such failure or default is to cause, or permit the holder or holders thereof to cause indebtedness in

an aggregate amount of $10,000 or more to become due prior to its stated date of maturity.

(d) Payor

(i) files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the

relief of, or relating to, debtors, now or hereafter in effect; (ii) makes any assignment for the benefit of creditors or takes any corporate

action in furtherance of any of the foregoing; (iii) applies for or consents to the appointment of a receiver, trustee, liquidator or

custodian of itself or of all or a substantial part of its property; (iv) is unable, or admits in writing its inability, to pay its debts

generally as they mature, (v) is dissolved or liquidated; (vi) becomes insolvent (as such term may be defined or interpreted under any

applicable statute); or (vii) takes any action for the purpose of effecting any of the foregoing.

(e) An

involuntary petition is filed against Payor (unless such petition is dismissed or discharged within thirty (30) days under any bankruptcy

statute now or hereafter in effect) or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official)

is appointed to take possession, custody or control of any property of Payor.

(f) A

final judgment or order for the payment of money in excess of $10,000 is rendered against Payor and the same shall remain undischarged

for a period of ten (10) days during which execution shall not be effectively stayed, or any judgment, writ, assessment, warrant of attachment,

or execution or similar process shall be issued or levied against the Collateral (as defined below) and such judgment, writ, or similar

process shall not be released, stayed, vacated or otherwise dismissed within ten (10) days after issue or levy.

(g) Any

cessation of operations by Payor.

Page 2 of 5

(h) The

sale, conveyance, or disposition of all or substantially all of the assets of Payor, the effectuation by Payor of a transaction or series

of related transactions in which more than 50% of the voting power of Payor is disposed of or transferred, or the consolidation, merger

or other business combination of Payor with or into any other Person (as defined below) or Persons when Payor is not the survivor. “Person”

shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

7. Upon

the occurrence or existence of any Event of Default, immediately and without notice, all outstanding obligations payable by Payor hereunder

shall become immediately due and payable. In addition to and not in lieu of the foregoing remedies, upon the occurrence or existence of

any Event of Default, Holder may exercise all other rights, powers or remedies granted to it under this Note, the other Transaction Agreements

or otherwise permitted to it by law (including but not limited to foreclosure of the security interest granted in the Security Agreement),

either by suit in equity or by action at law, or both, all such remedies being cumulative.

8. Payor

shall provide Holder with written notice of any Event of Default within two (2) business days of the occurrence, commencement, or recurrence

of such Event of Default.

9. Payor

agrees that the indebtedness evidenced by this Note and the other note issued pursuant to the Loan Agreement are secured by a pledge of

all the Company’s assets, as set forth in the Loan Agreement. The Company agrees to take such actions and execute such documents

as Holder reasonably requests to perfect Lenders’ security interest in the Company’s assets.

10. So

long as Payor shall have any obligation under the Transaction Agreements, Payor shall not, without Lenders’ written consent, lend

money, give credit (other than in relation to the sale or loan of MyoVista units or related supplies and accessories in the normal course

of business), or make advances to any person, firm, joint venture or corporation or other entity, including, without limitation, officers,

directors, employees, subsidiaries and affiliates of Payor, except loans, credits or advances in existence or committed on the date hereof

and which Payor has informed Lenders in writing prior to the date hereof.

11. So

long as Payor shall have any obligation under the Transaction Agreements, Payor shall not, without Lenders’ prior written consent,

assume, guarantee, endorse, contingently agree to purchase or otherwise become liable upon the obligation of any person, firm, partnership,

joint venture or corporation, except by the endorsement of negotiable instruments for deposit or collection and except assumptions, guarantees,

endorsement and contingencies in existence or committed on the date hereof and which Payor has informed Lenders in writing prior to the

date hereof.

12. Payor

waives presentment for payment, demand, protest and notice of protest and of nonpayment. No failure by Holder to exercise, or delay by

Holder in exercising, any right or remedy hereunder shall operate as a waiver thereof or of any other right or remedy and no single or

partial exercise of any right or remedy shall preclude any other or further exercise thereof or of any other right or remedy. Holder may

not waive any of its rights except by an instrument in writing signed by it.

Page 3 of 5

13. Notwithstanding

any other provision of this Note, interest under this Note shall not exceed the maximum rate permitted by applicable law, and if any amount

is paid under this Note as interest in excess of such maximum rate, then the amount so paid will not constitute interest but will constitute

a payment on account of the principal amount of this Note. If such excessive interest exceeds the unpaid principal balance of this Note,

such excess shall be refunded to Payor.

14. This

Note shall be binding upon and shall inure to the benefit of Payor and Holder and their respective successors and assigns. Payor may not

transfer or assign any of its rights or obligations under this Note without the prior written approval of Holder, which may be withheld

in Holder’s sole and absolute discretion. This Note may not be amended or modified orally, but only by an amendment in writing signed

by Payor and Holder

15. If

any provision of this Note shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability

of the remaining provisions shall not in any way be affected or impaired thereby.

16. This

Note shall be governed by and construed under the laws of the State of Texas, as applied to agreements among Texas residents made and

to be performed entirely within the State of Texas, without giving effect to conflicts of laws principles that would result in the application

of any law other than Texas law.

17. In

addition to the obligations recited herein and contemplated to be performed, executed, and/or delivered by Payor, Payor agrees to perform,

execute, and/or deliver or cause to be performed, executed, and/or delivered any and all such further acts, instruments, deeds, and assurances

as may be reasonably required by Lenders to consummate all transactions contemplated hereby or by the Transaction Agreements.

[Remainder

of this page deliberately left blank]

Page 4 of 5

IN WITNESS WHEREOF, Payor

and Holder have caused this Note to be executed as of the date first written above.

PAYOR:

HEARTSCIENCES INC., a Texas corporation

By:

/s/ Andrew Simpson

Name:

Andrew Simpson

Title:

CEO

HOLDER:

FRONT RANGE VENTURES, LLC,

a Wyoming limited liability company

By:

/s/ Alix Storrer

Name:

Alix Storrer

Title:

AVP, Trust Officer

Page 5 of 5

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Cover

Sep. 29, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 29, 2026

Entity File Number

001-41422

Entity Registrant Name

HEARTSCIENCES

INC.

Entity Central Index Key

0001468492

Entity Tax Identification Number

26-1344466

Entity Incorporation, State or Country Code

Entity Address, Address Line One

550 Reserve Street

Entity Address, Address Line Two

Suite 360

Entity Address, City or Town

Southlake

Entity Address, State or Province

Entity Address, Postal Zip Code

76092

City Area Code

682

Local Phone Number

237-7781

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

HSCS

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

HSCSW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HSCS_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: